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Sphingosine-1-phosphate (S1P) has been reported as a matriptase activa-
tor. The aim of this study was to reveal if S1P can influence hepcidin production. 
Furthermore, we investigated how S1P can affect the viability and the redox sta-
tus of primary hepatocytes. Rat primary hepatocytes were cultivated for 72 h and 
were treated with 50, 200, 1000 ng/ml S1P. Cell-free supernatants were collected 
every 24 h. Cell viability was tested by a colorimetric method using tetrazolium 
compound (MTS). The hepcidin levels in the cell-free supernatants were exam-
ined with hepcidin sandwich ELISA to determine the effect of S1P on the hep-
cidin-modulating ability of matriptase. In order to estimate the extent of S1P- 
generated oxidative stress, extracellular H2O2 measurements were performed by 
the use of fluorescent dye. Based on the findings, S1P treatment did not cause cell 
death for 72 h at concentrations up to 1000 ng/ml. S1P did not influence the ex-
tracellular H2O2 production for 72 h. The hepcidin levels were significantly sup-
pressed in hepatocytes exposed to S1P treatment. Further studies would be needed 
to explore the exact mechanism of action of S1P.  
Key words: Matriptase, hepcidin, sphingosine-1-phosphate, rat primary 
hepatocytes 
The major internal detoxification organ in mammals is the liver, which 
serves a wide spectrum of vital functions. Liver cells are divided into hepato-
cytes, Kupffer cells, and endothelial cells. Transformed hepatocyte cell lines, for 
example rat hepatoma H-4-II-E cells (Kovacs et al., 1977) cannot adequately 
mimic the phenotype of the liver. In contrast, the primary cells were isolated di-
rectly from the tissues and therefore have a normal cell morphology and are ca-
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pable of maintaining many of the markers and functions seen in vivo (Pan et al., 
2009). The rat primary hepatocyte model is an important tool for hepatic toxicol-
ogy studies. However, it is well reported that primary cells have a limited life-
time (2–4 days) (Soldatow et al., 2013). 
Matriptase-1 (MT-1, also known as epithin) and matriptase-2 (MT-2, also 
known as TMPRSS6) belong to the type II transmembrane serine protease family 
(TTSP) (Hooper et al., 2001), more precisely to the matriptase subfamily (Szabo 
and Bugge, 2008). MT-1 is widely expressed in epithelial tissues, with high lev-
els in the gastrointestinal tract, prostate (Takeuchi et al., 1999), normal and can-
cerous breast, ovarian and colon tissues (Oberst et al., 2003). MT-1 is required 
for postnatal survival. According to Oberst et al. (2001), MT-1 has a potential role 
in cancer invasion and metastasis in some types of cancer. 
MT-2 has been found in high levels in the liver and in small amounts in 
the kidney (Hooper et al., 2003). MT-2 is structurally similar to MT-1 (Sanders 
et al., 2010). Silvestri et al. (2008) identified the membrane-bound haemojuvelin as 
a substrate for MT-2 in vitro. MT-2 can regulate the iron homeostasis (Folgueras 
et al., 2008). Hepcidin is a systemic iron regulatory hormone, secreted by the liver 
(Du et al., 2008). It modulates the iron absorption via duodenal enterocytes (Ni-
colas et al., 2001). Hepcidin negatively regulates the iron export by promoting 
the degradation of ferroportin, which is an iron exporter located on the surface of 
intestinal enterocytes, macrophages, and hepatocytes (Nemeth et al., 2004). MT-
2 cleaves membrane-bound haemojuvelin which is the main activator of hepcidin 
transcription (Silvestri et al., 2008). Dysfunction of matriptase-2 (MT-2) can be in-
volved in iron regulatory disorders via altered regulation of hepcidin expression. 
Both MT-1 and MT-2 are anchored to the cell surface (Takeuchi et al., 
2000; Hooper et al., 2003) and can undergo autocatalytic activation in vitro 
(Takeuchi et al., 1999; Ramsay et al., 2009). 
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite. 
Most cells can synthesise S1P which is an intracellular second messenger and ex-
tracellular mediator in mammalian cells (Yatomi et al., 2001). S1P regulates a 
wide variety of biological responses, for example angiogenesis, vascular matura-
tion, cardiac development and immunity, and is important for cell proliferation, 
cell survival and cell movement. There are five G-protein-coupled S1P receptors 
which enable regulation of numerous downstream signalling pathways. The role 
of S1P depends on the relative expression of these receptors (Spiegel and Mils-
tien, 2003). Benaud et al. (2002) determined a novel biological function of S1P 
as an activator of matriptase in epithelial cells. It was also demonstrated that bio-
active phospholipids can activate cell surface proteases (Benaud et al., 2002). 
The aim of this study was to investigate the possible relationship between 
S1P and hepcidin production in a rat primary hepatocyte model. Firstly, we esti-
mated the cytotoxic properties of S1P and then we also investigated the effect of 
S1P on baseline extracellular H2O2 production. The changes in hepcidin levels in 
cell-free supernatants were also quantified. 
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Materials and methods 
Cells and culture conditions 
Cryopreserved primary rat hepatocytes, isolated from male Sprague-Dawley 
rats, were purchased from Thermo Fisher Scientific (Waltham, Massachusetts, 
USA). Cryopreserved cells were thawed at 37 °C, pipetted into hepatocyte thaw 
medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and centri-
fuged with 100 × g for 10 min. Hepatocytes were seeded on membrane insert plate 
(Costar Transwell permeable supports, 0.4 µm polyester membrane 24 mm insert, 
6-well plate, tissue culture treated, Merck, Germany) or 96-well plate (Merck, 
Darmstadt, Germany). The seeding density was 0.9–1.1 × 106 cells/ml, in 2 ml 
apical medium. Before seeding the cells, viability was checked by Trypan blue 
staining (1:8 dilutions, 1 min, Merck, Germany). The maintenance medium was 
Williams E medium (Thermo Fisher Scientific, USA) supplemented with 
10,000 IU/ml penicillin, 10 mg/ml streptomycin, 2 mM glutamine, 0.2 IU/ml insu-
lin, 4 µg/l dexamethasone, and 0.22% bicarbonate. Fetal bovine serum (10% FBS) 
was added to the medium only in the first 6 h after thawing. The maintenance 
medium without FBS was then used and replaced every 24 h. The cells were in-
cubated at 37 °C, 5% CO2. 
Exposure of primary hepatocytes to S1P 
S1P was purchased from Bio-Techne (Minneapolis, Minnesota, United 
States). S1P was dissolved in phosphate-buffered saline with 4 mg/ml bovine se-
rum albumin, which was the stock solution (0.5 mg/ml). After the first 6 h, S1P 
was added to the medium apically at 50, 200 or 1000 ng/ml. The maintenance 
medium with S1P was changed every 24 h. The treatment time was 72 h. 
MTS assay for cell viability 
The hepatocytes were seeded in a 96-well plate and incubated with 50, 
200 or 1000 ng/ml S1P for 72 h. The control wells were incubated with mainte-
nance medium only. After the medium was removed, 100 µl maintenance medi-
um was added with 20 µl CellTiter96 aqueous one solution (Promega, Biosci-
ence, Hungary) in every well. This reagent contained the tetrazolium compound 
MTS (Cory et al., 1991). The assay protocol is based on the reduction of the 
MTS tetrazolium compound by viable cells to generate a coloured formazan dye 
that is soluble in cell culture media. This conversion is reported to be carried out 
by NAD(P)H-dependent dehydrogenase enzymes in metabolically active cells. 
The cells were incubated with the dye for 2 h at 37 °C, 5% CO2. The absorbance of 
formazan was measured by EZ Read Biochrom 400 microplate reader at 490 nm 
wavelength (Biochrom Ltd., UK). 
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Amplex Red assay for extracellular H2O2 level measurement 
Amplex Red Hydrogen Peroxide Assay Kit (Thermo Fisher Scientific, USA) 
was used to measure the concentration of H2O2 in cell-free supernatant from the 
apical compartment. Fluorescence ROS measurement was based on the fact that 
Amplex Red reagent reacts with H2O2 and horseradish peroxidase and it is con-
verted into fluorescent resorufin. The cells were treated with 50, 200 or 1000 ng/ 
ml S1P for 72 h. The samples were collected every 24 h; 50 µl cell-free superna-
tant and 50 µl Amplex Red working solution was used to determine the H2O2 
concentration. After 30 min of incubation at room temperature the samples were 
measured with Victor X2 2030 fluorometer at 560 nm excitation and 590 nm 
emission wavelength. 
Hepcidin sandwich ELISA for determination of hepcidin level 
To determine the concentration of hepcidin in the apical compartment from 
the cell-free supernatant, we used a rat hepcidin ELISA kit from Elabscience Bio-
technology (Houston, Texas, USA). After 24, 48 and 72 h of S1P treatment at 
50, 200 or 1000 ng/ml concentrations, the apical cell-free supernatants were col-
lected. The assay procedure was performed according to the manufacturer’s 
guidelines. The absorbance values were detected with EZ Read Biochrom 400 
microplate reader at 450 nm wavelength (Biochrom Ltd, UK). 
Statistical analysis 
Differences between groups were statistically analysed using one-way 
analysis of variance (ANOVA) with Tukey’s post hoc test, where the data were 
of normal distribution and the homogeneity of variances was confirmed. Statisti-
cal significance was set at P < 0.05. For statistical evaluation the R 2.14.2 soft-
ware package was applied (2012, Vienna, Austria). The results are expressed as 
means ± SDs. 
 
Results 
The effect of S1P on cell viability 
It was confirmed that even the highest concentration of S1P (at 1000 ng/ 
ml) did not cause significant cell death after 24-h (P = 0.96887) and 72-h (P = 
0.1960) treatment (Fig. 1). It was found that S1P administration for 72 h even at 
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Fig. 1. Assessment of cell viability after 24 and 72 h of incubation of rat primary hepatocytes with 
S1P at 50, 200 and 1000 ng/ml. The results represent average absorbance values of produced MTS 
formazan ± standard deviations. No significant differences were found between control and  
S1P- treated cells after 24 and 72 h of incubation. The results are representative of three  
independent experiments 
The assessment of H2O2 measurement 
We found that S1P did not cause a significant increase in the extracellular 
H2O2 levels at any applied concentrations within the investigated time period 
(P > 0.05 in each case) (Fig. 2). 
 
Fig. 2. The effects of S1P at 50, 200 and 1000 ng/ml on extracellular H2O2 production of rat  
primary hepatocytes. Cells were exposed to S1P for 24, 48 and 72 h. No significant differences 
were found between the control and the S1P-treated groups. The values represent the means of 
resorufin fluorescence intensities ± standard deviations (n = 3) 
S1P-caused changes in hepcidin levels 
It was found that the hepcidin levels in cell-free supernatants were signifi-
cantly decreased compared to control samples after 24 h of incubation at each 
concentration of S1P (at 50 ng/ml and 200 ng/ml: P < 0.001, at 1000 ng/ml: P < 
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0.01). Hepcidin production was significantly reduced when cells were treated 
with S1P at 200 ng/ml (P = 0.0206) and 1000 ng/ml (P < 0.001) after 48 h of in-
cubation (at 50 ng/ml: P = 0.8656). After 72-h administration of S1P, there were 
significant differences in hepcidin levels between the treated and the control 
samples (in the case of S1P at 50 ng/ml: P = 0.00124, in the case of S1P at 200 ng/ 
ml and at 1000 ng/ml: P < 0.001) (Fig. 3). 
 
Fig. 3. Absorbance values of hepcidin in rat primary hepatocytes exposed to S1P for 24, 48 and 
72 h. The hepcidin levels in the cell-free supernatant were significantly decreased after 24 h of  
incubation at all concentrations of S1P (50 ng/ml and 200 ng/ml: P < 0.001, 1000 ng/ml: P < 0.01). 
After 48 h incubation time S1P at 200 ng/ml (P = 0.0206) and at 1000 ng/ml (P < 0.001)  
significantly decreased the hepcidin levels. The hepcidin levels were significantly lower in the 
S1P-treated groups after 72 h of incubation (at 50 ng/ml: P = 0.00124, at 200 ng/ml and 
1000 ng/ml: P < 0.001) compared to control values. Data are presented as means of absorbance ±  




MT-1 has an important role in regulating the formation and integrity of the 
intestinal epithelial barrier (Buzza et al., 2010), development of the epidermis, 
hair follicles, and cellular immune system, and it is required for postnatal surviv-
al (List et al., 2002) via tight junction regulation. S1P as an extracellular media-
tor and intracellular second messenger can activate MT-1 in nanomolar concen-
trations (Benaud et al., 2002). 
In our earlier study, S1P was tested on IPEC-J2 non-tumorigenic cell line 
(Pászti-Gere et al., 2016). IPEC-J2 was isolated from the jejunum of a neonatal 
non-suckled piglet (Berschneider, 1989). The main advantages of IPEC-J2 cells 
were that they possess enterocyte-like microvilli and tight junctions (Schierack et 
al., 2006). Occludin, claudin-1, -3, -4, -5, -7, and -8 were also detected (Zakrzewski 
et al., 2013) in IPEC-J2 cells. Thus, the IPEC-J2 cell line more closely mimics in 
vivo conditions than other, tumorigenic cell lines (Vergauwen, 2015). In our pre-
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vious study it was found that S1P at 200 ng/ml concentration was not cytotoxic 
and did not cause an elevation in extracellular hydrogen peroxide levels. S1P had 
strong barrier protective effect, since the transepithelial electrical resistance was 
elevated and a higher amount of occludin appeared in cell membranes (Pászti-
Gere et al., 2016). 
MT-2 regulates the iron homeostasis via cleavage of membrane-bound 
haemojuvelin, which is a main activator of hepcidin transcription (Silvestri et al., 
2008). Hepcidin inhibits the entry of iron into the plasma and its absorption from 
enterocytes. It was also observed that mice with a TMPRSS6 –/– defect or the 
absence of matriptase-2 proteolytic activity have iron deficiency anaemia, upreg-
ulation in hepcidin transcription, and reduced protein levels of ferroportin on en-
terocytes (Du et al., 2008; Folgueras et al., 2008). Thus, stimulation of MT-2 ac-
tivation could be an alternative treatment of iron deficiency anaemia. 
Our aim was to elucidate the effects of S1P on MT-2 indirectly via moni-
toring hepcidin levels on rat primary hepatocytes. S1P regulates numerous 
downstream signalling pathways, for example cell proliferation, survival and cell 
motility (Spiegel and Milstien, 2003). The role of S1P was examined using sev-
eral different cells. In the liver the modulation of S1P can be a potential thera-
peutic target for the treatment of several hepatic diseases. It was observed that 
sphingolipid metabolites produce a significant upregulation of long-chain 
ceramides in the serum of patients with hepatocellular carcinoma (HCC) as com-
pared to patients with cirrhosis (Grammatikos et al., 2016). In contrast, S1P (be-
tween concentrations of 10 and 30 µM) reduced the HCC cell migration induced 
by hepatocyte growth factor in HuH7 cells (Matsushima-Nishiwaki et al., 2018). 
In mice, the S1P level and the expression of one of its receptors (S1P3) in the 
liver were up-regulated in cholestasis-induced liver fibrosis (Li et al., 2009). Two 
animal models of type 1 diabetes had elevated S1P levels compared to control 
mice (Fox et al., 2011). However, the role of S1P in hepatic dysfunctions has not 
been completely clarified yet. 
On the one hand, S1P could elevate H2O2 level in FRTL-5 thyroid cells 
(Okajima et al., 1997), while on the other hand Nakahara et al. (2012) described 
that S1P can inhibit the apoptosis of granulosa cells. 
Rat primary hepatocytes represent the in vivo conditions better than a he-
patoma cell line, therefore the modulating effect of S1P on matriptase activity 
can be better predicted. According to our findings, S1P, in the tested concentra-
tion range, did not affect cell viability and extracellular H2O2 levels significantly. 
Based on our results, the hepcidin levels significantly decreased in rat primary 
hepatocytes exposed to S1P after an incubation time of 24, 48 and 72 h. 
In conclusion, the application of S1P seems to be safe at 50, 200 and 
1000 ng/ml concentrations, because it did not increase the cell death rate of 
hepatocytes and did not disturb redox cell status. S1P treatment led to decreased 
hepcidin production; however, the changes in hepcidin levels were not fully de-
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pendent on S1P concentration. The results of this study indicate the beneficial 
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